Neoplasm malignant
RecruitingStudy of BI-1206 and Pembrolizumab for Patients with Advanced Solid Tumors Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy
Study of BI-1206 and Pembrolizumab for Patients with Advanced Solid Tumors Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy
- Disease:Neoplasm malignant
- Substances:PembrolizumabAnti-(Fc Fragment Of Igg Receptor Iib) Monoclonal Antibody Bi-1206
Sweden- Participants:18–64 years · 65+ years
- Substances:Pembrolizumab
- Sponsor:Bioinvent International AB














